Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Diagnostic Study Evaluating the Impact of P-tau217 Blood Biomarker Testing on Early Evaluation and Management of Patients Presenting With Cognitive Complaint in Primary and Secondary/Tertiary Care

NCT07140744 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT07140744
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07140744 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Diagnostic Study Evaluating the Impact of P-tau217 Blood Biomarker Testing on Early Evaluation and Management of Patients Presenting With Cognitive Complaint in Primary and Secondary/Tertiary Care
Lead sponsor
Eli Lilly and Company
Phase
Not applicable
Overall status
Recruiting
Start date
August 22, 2025
Completion date
October 31, 2027
Enrollment
7,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

subjective cognitive impairment